The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
News
PANCREATIC CANCER
MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
GYNECOLOGICAL CANCER
FDA reviewing oral combination treatment for ovarian cancer
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
PANCREATIC CANCER
Fluorescent dye assists in surgical removal of small pancreatic tumors
Fluorescent imaging can safely help surgeons find and remove small tumors in the pancreas, according to a recent report. The case study describes how the…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
PANCREATIC CANCER
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment